🇺🇸 FDA
Pipeline program

SPT-300

SPT-300-2024-203

Phase 2 small_molecule active

Quick answer

SPT-300 for Major Depressive Disorder (MDD) is a Phase 2 program (small_molecule) at Seaport Therapeutics with 2 ClinicalTrials.gov record(s).

Program details

Company
Seaport Therapeutics
Indication
Major Depressive Disorder (MDD)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials